Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 18

recruiting
3 977
countries
28
conditions
2 106

973 trials match your criteria

Varicella

Recruiting

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896

Study of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ibuzatrelvir

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.